We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

124 hedge funds and large institutions have $549M invested in Enanta Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 36 increasing their positions, 42 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 21

35% more capital invested

Capital invested by funds: $408M → $549M (+$141M)

12% more funds holding

Funds holding: 111 → 124 (+13)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

14% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 42

62% less call options, than puts

Call options by funds: $1.13M | Put options by funds: $2.97M

Holders
124
Holders Change
+13
Holders Change %
+11.71%
% of All Funds
3.31%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
35
Increased
36
Reduced
42
Closed
21
Calls
$1.13M
Puts
$2.97M
Net Calls
-$1.84M
Net Calls Change
-$857K

Top Buyers

1
ACM
Apex Capital Management
Ohio
+$24M
2
State Street
State Street
Massachusetts
+$17.8M
3
BFA
BlackRock Fund Advisors
California
+$11.5M
4
EAM
Eagle Asset Management
Florida
+$8.23M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.67M

Top Sellers

1
SAM
Senzar Asset Management
New York
-$23.4M
2
RCM
RA Capital Management
Massachusetts
-$9.89M
3
GC
Guggenheim Capital
Illinois
-$7.39M
4
Marshall Wace
Marshall Wace
United Kingdom
-$5.45M
5
NI
Numeric Investors
Massachusetts
-$4.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
126
Renaissance Technologies
New York
– -$3.29M -83,277 Closed
CIP
127
Convergence Investment Partners
Florida
– -$2.1M -53,130 Closed
PP
128
PDT Partners
New York
– -$1.43M -36,096 Closed
SIM
129
Spark Investment Management
New York
– -$1.42M -35,800 Closed
GTC
130
Ghost Tree Capital
New York
– -$1.39M -35,000 Closed
WC
131
Wexford Capital
Florida
– -$1.26M -31,870 Closed
GLA
132
Great Lakes Advisors
Illinois
– -$1.14M -28,862 Closed
Two Sigma Investments
133
Two Sigma Investments
New York
– -$970K -24,512 Closed
AI
134
Axiom Investors
Connecticut
– -$619K -15,640 Closed
Arrowstreet Capital
135
Arrowstreet Capital
Massachusetts
– -$606K -15,322 Closed
Prudential Financial
136
Prudential Financial
New Jersey
– -$592K -14,970 Closed
Allianz Asset Management
137
Allianz Asset Management
Germany
– -$239K -6,030 Closed
Jane Street
138
Jane Street
New York
– -$237K -5,981 Closed
D.E. Shaw & Co
139
D.E. Shaw & Co
New York
– -$224K -5,673 Closed
PA
140
Perceptive Advisors
New York
– -$120K -3,040 Closed
BNP Paribas Financial Markets
141
BNP Paribas Financial Markets
France
– -$32.1K -811 Closed
Group One Trading
142
Group One Trading
Illinois
– -$6K -162 Closed
PTC
143
Private Trust Company
Ohio
– -$2K -47 Closed
KT
144
Kanaly Trust
Texas
– -$2K -45 Closed
FPFS
145
First Personal Financial Services
North Carolina
– +$806 +18 New
2 3 4 5
6

ENTA Hedge Fund Activity: Q4 2014 in Review

124 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2014, worth a combined $549M — up 35% from $408M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ENTA positions and 21 closed out — a net gain of 14 holders — while 36 added to existing stakes and 42 trimmed.

The largest buyer was Apex Capital Management, adding an estimated $24M. The largest seller was Senzar Asset Management, cutting an estimated $23.4M.

  • 124 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2014, up from 111 in Q3 2014.
  • Funds reported $549M of Enanta Pharmaceuticals stock for Q4 2014, up 35% quarter-over-quarter.
  • 35 funds opened new Enanta Pharmaceuticals positions in Q4 2014 and 21 closed out, a net change of +14 holders.
  • The largest Enanta Pharmaceuticals buyer in Q4 2014 was Apex Capital Management, an estimated $24M added.
  • The largest Enanta Pharmaceuticals seller in Q4 2014 was Senzar Asset Management, an estimated $23.4M sold.

Based on aggregated 13F filings for Q4 2014.